Craig Hallum downgraded shares of Bioventus (NYSE:BVS – Get Rating) from a buy rating to a hold rating in a report issued on Tuesday morning, MarketBeat.com reports. They currently have $10.00 target price on the stock.
A number of other brokerages also recently commented on BVS. JPMorgan Chase & Co. downgraded shares of Bioventus from an overweight rating to an underweight rating in a research note on Wednesday, November 9th. Canaccord Genuity Group downgraded shares of Bioventus from a buy rating to a hold rating and reduced their price objective for the stock from $18.00 to $6.00 in a research note on Wednesday, November 9th. Morgan Stanley reduced their price objective on shares of Bioventus from $11.00 to $5.00 and set an overweight rating for the company in a research note on Thursday, November 10th. Finally, Canaccord Genuity Group downgraded shares of Bioventus from a buy rating to a hold rating and reduced their price objective for the stock from $18.00 to $6.00 in a research note on Wednesday, November 9th. One analyst has rated the stock with a sell rating, four have given a hold rating and one has assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of Hold and an average price target of $8.80.
Bioventus Stock Performance
Bioventus stock opened at $1.81 on Tuesday. The company has a market capitalization of $140.19 million, a PE ratio of -6.07 and a beta of 1.85. Bioventus has a fifty-two week low of $1.65 and a fifty-two week high of $15.57. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.05 and a current ratio of 1.39. The company has a 50 day moving average price of $6.25 and a 200-day moving average price of $7.57.
Institutional Investors Weigh In On Bioventus
Bioventus Inc a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products.
- Get a free copy of the StockNews.com research report on Bioventus (BVS)
- After Nixing its 13% Dividend, Is Lumen Technologies Okay To Own?
- The Sell-Side Caps Gains In Dick’s Sporting Goods
- Cisco Systems Hopes Restructuring Cuts Costs to Drive Revenue
- Want to Get a 10% Dividend Yield, Look Here
- Stock-ing Stuffers: 3 Attractive Stocks Trading Around $10
Receive News & Ratings for Bioventus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioventus and related companies with MarketBeat.com's FREE daily email newsletter.